Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | |  What to know The FDA declined to review Moderna’s mRNA flu vaccine application, citing inadequate study design. Moderna was surprised, having previously engaged with the FDA on trial design. The vaccine is under review in Europe, Canada and Australia. The decision comes amid a shift in U.S. vaccine approval policies and skepticism about mRNA technology. Summary is generated by AI. Please verify accuracy by reading the full article. What are your thoughts on the FDA's decision to decline reviewing Moderna's mRNA-based flu vaccine application? | | | | Column Judith Martin, Nicholas Martin and Jacobina Martin | | | | How was today's newsletter? | | | | | | | | |
Have a question? Ask the Post AI to learn more 
